At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
Molnupiravir 200 mg +3 moredrug
Likely dose
Molnupiravir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19
In Brief
A Phase 2 clinical trial evaluating Molnupiravir 200 mg, Molnupiravir 400 mg, and 2 other interventions for SARS-CoV-2 Infection, COVID-19. Completed, enrolled 204 participants across 10 sites.
Detailed Summary
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA detection in symptomatic adult outpatients with COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection, COVID-19
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedMay 28, 2020
Enrollment StartJun 19, 2020
Primary CompletionFeb 21, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago
Interventions
Molnupiravir 200 mgdrug
Oral capsule of molnupiravir
Molnupiravir 400 mgdrug
Oral capsule of molnupiravir
Molnupiravir 800 mgdrug
Oral capsule of molnupiravir
Placebo (PBO)drug
placebo oral capsule